Business
Update on settlement
Update on settlement.
About this update from Faron Pharmaceuticals Oy
[{"type":"text","content":"\n\nFaron Pharmaceuticals Ltd\n(\"Faron\" or the \"Company\")\nUpdate on settlement under the UK Open Offer and the REX Retail Offer\nNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, NEW ZEALAND OR THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.\n \nTHIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE OR CONTAIN ANY INVITATION, SOLICITATION, RECOMMENDATION, OFFER OR ADVICE TO ANY PERSON TO ACQUIRE ANY SECURITIES. PLEASE SEE THE IMPORTANT NOTICES AT THE END OF THIS ANNOUNCEMENT.\n \nCompany announcement, 25 June 2024 at 4pm (EEST) / 2pm (BST) / 9am (EDT)\n \nTURKU, FINLAND - Faron Pharmaceuticals Ltd (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company pursuing a CLEVER-1 receptor targeting approach to reprogramming myeloid cells to activate anti-tumor immunity in hematological and solid tumor microenvironments, announces an update on settlement of the UK Open Offer and the REX Retail Offer, which are part of the fully subscribed EUR 30.7 million share offering. Capitalised terms used but not defined herein have the meaning given to them in the announcement of final results of the share offering dated 20 June 2024.\n \nThe New Shares were admitted to trading on First North and AIM at 8:00 a.m. BST on 24 June 2024. Due to a technical delay with settlement, CREST accounts are now expected to be credited in respect of shares under the UK Open Offer on 26 June 2024 and settlement of the REX Retail Offer is expected to occur on 25 June 2024.\n \n \nFaron Pharmaceuticals Ltd\n \nFor more information please contact:\nICR Consilium Mary-Jane Elliott, David Daley, Lindsey Neville\nPhone: +44 (0)20 3709 5700\nE-mail: [email protected]\n \nCairn Financial Advisers LLP, Nomad\nSandy Jamieson, Jo Turner\nPhone: +44 (0) 207 213 0880\n \nPeel Hunt LLP, Broker\nChristopher Golden, James Steel\nPhone: +44 (0) 20 7418 8900\n \nSisu Partners Oy, Certified Adviser on Nasdaq First North\nJuha Karttunen\nPhone: +358 (0)40 555 4727\nJukka Järvelä\nPhone: +358 (0)50 553 8990\n \nAbout BEXMAB\n \nThe BEXMAB study is an open-label Phase I/II clinical trial investigating bexmarilimab in combi...